Total Funding
20
Total FundingSeries B raised
Growth Score
pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
403806
Fovea Pharmaceuticals is a French biopharmaceutical company that discovers and develops drugs for the treatment of ocular diseases.
- Pierre Belichard: Founder & COOPast Role: Sanofi, VP Business Development - Ophthalmology
About the Company
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases.
The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the
treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration.
Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.
